The GlaxoSmithKline, Sanofi Ventures and 6 Dimensions Capital-backed genetically-defined disease therapy developer has filed for an $86.3m offering.

Genetic sequencing spinout Oxford Nanopore is the latest to be hit by the Woodford saga, with reports that the fund manager is looking to sell off its stake.

Having initially targeted $115m in proceeds, the genome sequencing spinout of Stanford has closed its offering at $140m after a full exercise of the overallotment option.

Boston Scientific has backed the 3x5 Partners-led round, which will be used by the medical device maker to expand its clinical research program abroad and initiate trials in the US.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The combined value of Woodford's stakes in immunotherapy developer Immunocore has reportedly crashed to $57m from around $112m.

BlueCross BlueShield Venture Partners, Ascension Ventures and Echo Health Ventures are all set to exit patient management software producer Phreesia, which has raised $109m in VC funding.

The total size of investments from the Cambridge-allied patient capital fund rose from $45.8m in 2017-2018, following a $196m fundraising effort earlier this year.

Sino-Singapore Healthcare Fund will back businesses in Southeast Asia, and Sinopharm has also taken part in a $20m series B round for one of its other partners, Novena Global Lifecare.

The care analysis software provider collected $10.3m in a round that included commitments from Spectrum Health Ventures and Ziegler LinkAge Longevity Fund.